Background: Lower socioeconomic status (SES) is linked to poorer neurocognitive development in the general population, but these effects in pediatric brain tumor survivors are underexplored. We examined the relationship between parental SES, clinical factors, and neurocognitive functioning longitudinally up to 5 years post-diagnosis and determined whether young children were more vulnerable. Methods: This population-based registry study included Swedish children diagnosed with brain tumors between 2008 and 2023 and who completed ≥2 neurocognitive assessments. Parental education, occupation, and household income were used as individual SES indicators as well as a combined SES measure. Linear mixed models examined relationships between SES and age at diagnosis on neurocognitive outcomes, accounting for time since diagnosis, chemotherapy, and radiotherapy. Results: We included 461 children (mean age at diagnosis = 7.98 years, SD = 4.01). Higher SES was associated with higher neurocognitive z-scores on processing speed (B = 0.23), working memory (B = 0.25), nonverbal reasoning (B = 0.29), verbal reasoning (B = 0.41), and global cognition (B = 0.42; q’s ≤ .039). No interactions between SES and age or time were observed. Longer time since diagnosis was associated with lower processing speed (B = −0.04) and verbal reasoning (B = −0.05; q’s ≤ .041). Younger age at diagnosis was related to steeper declines in nonverbal reasoning (B = 0.01, q = .016). Cranio-spinal irradiation was related to lower processing speed (B = −0.50, q = .019). Conclusions: In Swedish childhood brain tumor survivors, lower SES was associated with poorer neurocognitive functioning over time. The absence of socioeconomic differences in rate of decline suggests that lower SES may reduce baseline cognitive reserve rather than amplifying disease or treatment-related toxicity.
Neurocognitive impairments are common in paediatric central nervous system (CNS) tumours and can relate to clinical and demographic factors. The impact of social or environmental factors, such as family psychosocial risk, is less well understood. We examined neurocognitive functioning in children with CNS tumours shortly after diagnosis and associations with psychosocial risk. This cohort study included children who underwent neuropsychological assessments within three months of diagnosis. Proportion, chi‐square and t ‐tests were used to compare neurocognitive outcomes to norms and evaluate prevalence of neurocognitive impairment (International Cognition and Cancer Task Force criteria: two scores at z ≤ −1.5, one score at z ≤ −2 or both). Regression analyses examined associations between psychosocial risk, age at diagnosis and neurocognitive outcomes, controlling for medical factors. We included 125 children (47 females; mean age at diagnosis = 9.7 years) assessed at an average of 2.08 months after diagnosis. A larger proportion of patients demonstrated neurocognitive impairments than normative expectations ( p = .002), with a greater likelihood for children from increased psychosocial risk groups ( p = .014). Increased psychosocial risk was associated with lower parent‐reported executive functioning ( p = .028), but not with other neurocognitive outcomes. Midline tumour location was related to better working memory; history of obstructive hydrocephalus was related to poorer verbal memory and chemo/radiotherapy initiation was related to poorer processing speed ( p 's < .05). A sub‐group of children with CNS tumours show neurocognitive impairments shortly after diagnosis. Children with increased family psychosocial risk were at higher risk of impairment. Psychosocial risk can help identify neurocognitively vulnerable children, highlighting the importance of both neuropsychological and psychosocial screening.